|
|
 Previous Article | Table of Contents | Next Article 
Nodular histiocytic lymphoma: an aggressive nodular lymphoma with potential
for prolonged disease-free survival
CK Osborne, L Norton, RC Young, AJ Garvin, RM Simon, CW Berard, S Hubbard and VT DeVita
Nodular histiocytic lymphoma (NH) is uncommon, and its natural history is
not well defined. Of 473 patients with non-Hodgkin's lymphoma, we found 16
(3.4%) with NH. Most patients (13/16) presented with pathologic stage (PS)
III or IV disease, including 7 with liver involvement. One patient (PS III)
was initially treated with cyclophosphamide alone, and 4 patients received
only radiotherapy, and none were long-term survivors. Eleven patients
received combination chemotherapy, and 8 achieved complete remission. Only
one of these patients relapsed and died at 19 mo; the other 7 continue in
complete remission without maintenance therapy with a minimum followup of
4.5 yr. The survival of the entire group of patients with NH is
intermediate between that of the other nodular lymphomas and diffuse
histiocytic lymphoma. Nine of 16 patients had either a repeat lymph node
biopsy during the course of their disease or lymph node examination at
autopsy. Lymph node histology in the majority converted to a diffuse, less
differentiated subtype of lymphoma. NH has a natural history similar to
that of diffuse histiocytic lymphoma and should be approached with the same
therapeutic strategy.
Volume 56,
Issue 1,
pp. 98-103,
07/01/1980
Copyright © 1980 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. J. Overman, L. Feng, B. Pro, P. McLaughlin, M. Hess, F. Samaniego, A. Younes, J. E. Romaguera, F. B. Hagemeister, L. Kwak, et al.
The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma
Ann. Onc.,
March 1, 2008;
19(3):
553 - 559.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K. Ganti, D. D. Weisenburger, L. M. Smith, C. P. Hans, R. G. Bociek, P. J. Bierman, J. M. Vose, and J. O. Armitage
Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: the Nebraska Lymphoma Study Group Experience
Ann. Onc.,
June 1, 2006;
17(6):
920 - 927.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. P. Hans, D. D. Weisenburger, J. M. Vose, L. M. Hock, J. C. Lynch, P. Aoun, T. C. Greiner, W. C. Chan, R. G. Bociek, P. J. Bierman, et al.
A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival
Blood,
March 15, 2003;
101(6):
2363 - 2367.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Ott, T. Katzenberger, A. Lohr, S. Kindelberger, T. Rudiger, M. Wilhelm, J. Kalla, A. Rosenwald, J. G. Muller, M. M. Ott, et al.
Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3
Blood,
May 15, 2002;
99(10):
3806 - 3812.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Rodriguez, P. McLaughlin, F.B. Hagemeister, L. Fayad, M.A. Rodriguez, M. Santiago, M. Hess, J. Romaguera, and F. Cabanillas
Follicular Large Cell Lymphoma: An Aggressive Lymphoma That Often Presents With Favorable Prognostic Features
Blood,
April 1, 1999;
93(7):
2202 - 2207.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
